Table 2 Patients’ characteristics of in different groups (EBER cut-off: 50%).
Variable | Number. (%) | All patients (N = 250) | P value | Elderly group | P value | Young group | P value | |||
|---|---|---|---|---|---|---|---|---|---|---|
EBV+ | EBV− | EBV+ | EBV− | EBV+ | EBV− | |||||
Number. (%) | Number. (%) | Number. (%) | ||||||||
Age | 250 | 26 | 224 | 19 | 147 | 7 | 77 | |||
>50y | 166 (66.4) | 19 (73.1) | 147 (65.6) | 19 (100) | 147 (65.6) | NA | NA | NA | NA | |
≤50y | 84 (33.6) | 7 (26.9) | 77 (34.4) | NA | NA | 7 (100) | 77 (34.4) | |||
Sex | 250 | 26 | 224 | 19 | 147 | 7 | 77 | |||
Male | 144 (57.6) | 21 (80.8) | 123 (54.9) | 0.012 | 15 (78.9) | 80 (54.4) | 0.042 | 6 (85.7) | 43 (55.8) | 0.230 |
Female | 106 (42.4) | 5 (19.2) | 101 (45.1) | 4 (21.1) | 67 (45.6) | 1 (14.3) | 34 (44.2) | |||
Site | 250 | 26 | 224 | 19 | 147 | 7 | 77 | |||
Extranodal | 106 (41.6) | 11 (42.3) | 95 (42.4) | 0.992 | 9 (47.4) | 68 (46.3) | 0.927 | 2 (28.6) | 27 (35.1) | 1.000 |
Lymph node | 144 (58.4) | 15 (57.7) | 129 (57.6) | 10 (52.6) | 79 (53.7) | 5 (71.4) | 50 (64.9) | |||
Stage | 250 | 26 | 224 | 19 | 147 | 7 | 77 | |||
I/II | 125 (50.0) | 6 (23.1) | 119 (53.1) | 0.004 | 4 (21.1) | 72 (49.0) | 0.021 | 2 (28.6) | 47 (61.0) | 0.122 |
III/IV | 125 (50.0) | 20 (76.9) | 105 (46.9) | 15 (78.9) | 75 (51.0) | 5 (71.4) | 30 (39.0) | |||
ECOG PS | 238 | 20 | 218 | 13 | 146 | 7 | 72 | |||
0–1 | 207 (83.5) | 14 (70.0) | 193 (88.5) | 0.001 | 9 (69.2) | 126 (86.3) | 0.111 | 5 (71.4) | 67 (93.1) | 0.115 |
2–4 | 31 (16.5) | 6 (30.0) | 25 (11.5) | 4 (30.8) | 20 (13.7) | 2 (28.6) | 5 (6.9) | |||
ESI | 242 | 21 | 221 | 14 | 145 | 7 | 76 | |||
0–1 | 194 (80.2) | 16 (76.2) | 178 (80.5) | 0.577 | 10 (71.4) | 115 (79.3) | 0.501 | 6 (85.7) | 63 (82.9) | 1.000 |
>1 | 48 (19.8) | 5 (23.8) | 43 (19.5) | 4 (28.6) | 30 (20.7) | 1 (14.3) | 13 (17.1) | |||
IPI | 237 | 20 | 217 | 13 | 145 | 7 | 72 | |||
0–2 | 174 (73.4) | 11 (55.0) | 163 (75.1) | 0.051 | 6 (46.2) | 96 (66.2) | 0.224 | 5 (71.4) | 67 (93.1) | 0.115 |
3–5 | 63 (26.6) | 9 (45.0) | 54 (24.9) | 7 (53.8) | 49 (33.8) | 2 (28.6) | 5 (6.9) | |||
Treatment | 250 | 26 | 224 | 19 | 147 | 7 | 77 | |||
R-CHOP | 125 (50.0) | 23 (88.5) | 102 (45.6) | NA | 18 (94.7) | 59 (40.1) | NA | 5 (71.4) | 43 (55.8) | NA |
R-DA- EPOCH | 35 (14.0) | 2 (7.6) | 33 (14.7) | NA | 0 (0.0) | 28 (19.1) | NA | 2 (28.6) | 5 (6.5) | NA |
CHOP | 90 (36.0) | 1 (2.9) | 89 (39.7) | NA | 1 (5.3) | 60 (40.8) | NA | 0 (0.0) | 29 (37.7) | NA |
Response | 250 | 26 | 224 | 19 | 147 | 7 | 77 | |||
CR(u)/PR | 212 (84.8) | 18 (69.2) | 194 (86.6) | 0.037 | 13 (68.4) | 135 (91.8) | 0.008 | 5 (71.4) | 73 (94.8) | 0.076 |
No response | 38 (15.2) | 8 (30.8) | 30 (13.4) | 6 (31.6) | 12 (8.2) | 2 (28.6) | 4 (5.2) | |||
